Recurrent squamous cell lung carcinoma is a medical condition with active clinical research programs worldwide.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID	Title	Status	Phase
NCT03373760	Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer	COMPLETED	PHASE2
NCT02785952	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	ACTIVE_NOT_RECRUITING	PHASE3
NCT03377556	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	COMPLETED	PHASE2
NCT02965378	Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	COMPLETED	PHASE2/PHASE3
NCT00946712	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	TERMINATED	PHASE3
NCT02154490	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	COMPLETED	—
NCT02766335	Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	COMPLETED	PHASE2/PHASE3
NCT02785939	Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	COMPLETED	PHASE2/PHASE3
NCT02926638	Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	TERMINATED	PHASE2/PHASE3
NCT02785913	Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	COMPLETED	PHASE2

Related Pages

All Recurrent squamous cell lung carcinoma trials All trials in Houston, United States